Compare Home Depot Inc (HD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Incyte Corporation — how do they compare? Home Depot Inc trades at $290.74 (market cap $294.79B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Home Depot Inc is far larger — about 12.9× Incyte Corporation's market cap, and Home Depot Inc pays a 3.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Incyte Corporation for 33 Days on average.
| HD | INCY | |
|---|---|---|
Market Cap | $294.79B | $22.85B |
Volume | 8,693,917 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $129.93 |
52-Week Low | $281.15 | $83.80 |
Typical Hold Time | 139 Days | 33 Days |
Enterprise Value | $355.27B | $18.35B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $290.74, up 1.74% on the day, reflecting positive momentum amid a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 20.68, and a net income margin of 8.41%. Recent cash flow trends indicate significant investment activity, while analyst consensus remains optimistic with a $379.93 price target. News highlights institutional adjustments and focus on Pro segment growth amid housing market pressures.
The outlook for HD is supported by solid profitability and analyst confidence, but risks include weakening big-ticket demand and margin pressures from investments. Housing market volatility and rising mortgage rates present headwinds, yet long-term prospects are bolstered by strategic initiatives and resilient Pro customer demand.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
